One day before the July Fourth holiday, the stock of clinical-stage biotech Summit Therapeutics (SMMT 8.18%) exploded like a powerful fireworks display. Shares of the cancer-focused company leaped by 8%, on a media report that a well-known peer was interested in a licensing deal. That rise bettered the S&P 500's (^GSPC 0.83%) 0.8% increase by several orders of magnitude. 15 billion new reasons to consider the stockThe media outlet in question was Bloomberg, which that morning published an article asserting ...